Severe Undifferentiated Vasoplegic Shock Refractory to Vasoactive Agents Treated with Methylene Blue

<div>(a) The biochemical pathway of vasodilatory shock as a result of upregulation of the nitric oxide-cGMP pathway. (b) Methylene blue’s site of action, as a guanylyl cyclase inhibitor, resulting in increased vasomotor tone.</div>

Case Reports in Critical Care

fig2

Figure 2

Figure 2: Severe Undifferentiated Vasoplegic Shock Refractory to Vasoactive Agents Treated with Methylene Blue 